In October, a Central Drugs Standard Control Organisation (CDSCO) alert revealed that 59 drug samples, including those from reputed companies, were deemed “not of standard quality.” The alert, issued recently by CDSCO, reported that out of 1,105 tested samples, 61 were identified as substandard. Among these, two samples of unlabelled vials claiming to contain Tigecycline 50 mg and two samples of phenolic disinfecting multi-purpose surface cleaner-cum-deodoriser (Lytner) were included.
The total count of substandard samples was 59, as two drug samples were repeated during testing. The testing of these drug samples was conducted across various statutory laboratories authorized by CDSCO. Notable drugs among those declared “not of standard quality” include Cefixime Oral Suspension IP, Amoxycillin, Potassium Clavulanate and Lactic Acid Bacillus Tablets (GAMPCLAV-625 LB Tablets), Rabeprazole Sodium (Enteric Coated) and Domperidone (Sustained Release) Capsules (20 mg/30 mg), Diclofenac Sodium Tablets IP 50 mg, Albendazole Tablets I.P. 400 mg, Ofloxacin, Ornidazole, Itraconazole, Clobetasol Propionate Cream (Derma -RX Cream), and Vitamin C (Orange Syrup). The CDSCO’s alert underscores the need for vigilance and quality control in the pharmaceutical industry to ensure the safety and efficacy of drugs reaching consumers.
Post Your Comments